Endothelial nitric oxide synthase (eNOS) VNTR and eNOS -786 could determine outcomes in advanced hepatocellular carcinoma treated with sorafenib,
Baseline α-fetoprotein (AFP) levels may be a predictive marker for advanced hepatocellular carcinoma receiving ramucirumab.
Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.
By analyzing data from international databases, researchers develop an alternative to the Child-Pugh system.
Safety and efficacy of sorafenib, the standard of care for advanced hepatocellular carcinoma, in older patients, evaluated.
Linifanib and sorafenib had similar overall survival for the treatment of advanced hepatocellular carcinoma (HCC).
Duration of stability linked with overall survival in advanced hepatocellular carcinoma treated with the tyrosine kinase inhibitor sorafenib.
Reduction in summary relative risk of hepatocellular carcinoma with increased vegetable, but not fruit, intake.
Researchers continue to search for a molecular pathway or biomarker to improve treatment options for patients with sorafenib-refractory HCC.
CASI Pharmaceuticals announced that the FDA has granted Orphan Drug designation to ENMD-2076 for the treatment of hepatocellular carcinoma.
Researchers found no survival difference found between patients receiving everolimus or placebo.
The benefits of hepatocellular carcinoma screening are unclear in patients with chronic liver disease.
A new study in Western Europeans shows that vitamin D lowers the risk of developing hepatocellular carcinoma.
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma.
Measurement of α-fetoprotein detects hepatocellular carcinoma most accurately in patients without hepatitis C virus infection.
Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC).
The FDA has approved Guerbet's Lipiodol (ethiozed oil) injection for imaging of hepatocellular carcinoma tumors
Increased coffee consumption may reduce hepatocellular carcinoma risk across ethnicities, according to a study presented at the AACR Annual Meeting.
LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.
Data indicate that everolimus did not improve overall survival in patients with advanced HCC following sorafenib failure.
Sorafenib can be an effective treatment for a variety of cancers, but its use can come with significant GI side effects.
Anti-CLTA4 Immunotherapy Achieves Antitumor Effects in Small Study of Hepatitis C-Related Hepatocellular CarcinomaJuly 30, 2013
Immunotherapy targeting the CLTA4 protein in HCV-related HCC demonstrated modest extended survival in a disease that has a high mortality rate.
Despite HCC having a poor prognosis and high mortality, systemic antiangiogenesis therapies offer some hope to patients.
Forming a multidisciplinary clinic for patients with HCC resulted in improved survival, likely due to more streamlined care and earlier diagnosis, found research presented at SSO 2013.
Radiofrequency ablation might offer comparable survival rates when compared with liver surgery for patients with hepatocellular carcinoma.
Aspirin use, but not the use of other nonsteroidal anti-inflammatory drugs (NSAIDs), is associated with a reduced risk of developing hepatocellular carcinoma.
Patients with advanced unresectable hepatocellular carcinoma have a higher median overall survival when treated with drug eluting bead transarterial chemoembolization.
Drug-eluting beads are a new type of drug delivery system that may be able to decrease side effects and localize chemotherapy treatment in HCC patients.
The first patient has been treated in a phase 2 clinical trial of intravenous delivery JX-594 in patients with advanced hepatocellular carcinoma.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- European Society for Medical Oncology (ESMO) Renal Cell Carcinoma Practice Guidelines
- Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer
- Prognostic Factors for Survival in Ewing's Sarcoma Identified
- Surveillance Until Rituximab Retreatment Does Not Increase Anxiety in Non-Hodgkin Lymphoma
- Black Women Disproportionately Affected by Early-Stage Breast Cancer
- Is Ageism Affecting Patients with Prostate Cancer?
- Radiotherapy in Older Women with Early-Stage Breast Cancer after Conserving Treatment
- Continuation or Reintroduction of Bevacizumab Improves Outcomes in Colorectal Cancer
- Gleason Score 9-10 vs. Gleason 8 Associated with Worse Outcomes
- Elevated C-Reactive Protein Linked with Poor Prognosis in Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|